Page last updated: 2024-11-06

7-methylxanthine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

7-methylxanthine, also known as theophylline, is a naturally occurring methylxanthine alkaloid found in tea leaves and cacao beans. It acts as a bronchodilator, relaxing smooth muscles in the airways and increasing airflow. Theophylline is used medically to treat asthma and other respiratory conditions. It is also being studied for its potential use in treating other conditions such as cancer and Alzheimer's disease. Theophylline can be synthesized chemically by reacting 1,3-dimethylxanthine with methyl iodide. The compound is studied due to its diverse pharmacological effects and its potential therapeutic benefits in various conditions.'

Cross-References

ID SourceID
PubMed CID68374
CHEMBL ID321248
CHEBI ID48991
SCHEMBL ID235130
MeSH IDM0177088

Synonyms (49)

Synonym
7-methyl-2,3,6,7-tetrahydro-1h-purine-2,6-dione
1h-purine-2, 3,7-dihydro-7-methyl-
wln: t56 bn dn fmvmvj b1
xanthine, 7-methyl-
heteroxanthine
7-methylxanthine ,
nsc7861
nsc-7861
552-62-5
7-methylxanthin
heteroxanthin
PDSP2_001024
7-methyl-3,7-dihydro-1h-purine-2,6-dione
PDSP1_001040
inchi=1/c6h6n4o2/c1-10-2-7-4-3(10)5(11)9-6(12)8-4/h2h,1h3,(h2,8,9,11,12
CHEBI:48991 ,
3,7-dihydro-7-methyl-1h-purine-2,6-dione
einecs 209-019-0
nsc 7861
1h-purine-2,6-dione, 3,7-dihydro-7-methyl-
ccris 5818
7-methylxanthine, >=98.0% (hplc)
methyl xanthine
CHEMBL321248 ,
7-methyl-3h-purine-2,6-dione
unii-e9m81njm6g
e9m81njm6g ,
7-methylx
bdbm82522
cas_552-62-5
7-methyl-1h-purine-2,6(3h,7h)-dione
FT-0672370
AKOS015903147
methyl xanthine [inci]
methylxanthine, 7-
7-methyl xanthine
2,6-dihydroxy-7-methylpurine
SCHEMBL235130
7-methyl-2,6-dioxypurin
mfcd00037979
DTXSID60203696
7-methyl-7h-purine-2,6-diol
CS-W017879
HY-W017163
3,3-difluorobenzophenone
Q27121426
AS-56812
EN300-393798
PD055547

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Thus, the repeated dose study of 7-MX for 180 days may augment the possibility of using 7-MX clinically for the safe and effective treatment of myopia."( Sub-chronic and chronic toxicity evaluation of 7-methylxanthine: a new molecule for the treatment of myopia.
Jain, SK; Kaur, I; Paul, S; Sahajpal, NS; Singh, H, 2022
)
0.98

Dosage Studied

ExcerptRelevanceReference
"Groups of pigmented rabbits, six in each group, were dosed during 10 weeks with one of the substances under investigation, and one untreated group was the control."( Biochemical and ultrastructural changes in rabbit sclera after treatment with 7-methylxanthine, theobromine, acetazolamide, or L-ornithine.
Kobayashi, T; Olsen, EB; Ribel-Madsen, SM; Trier, K, 1999
)
0.53
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
oxopurine
purine alkaloid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (7)

PathwayProteinsCompounds
Caffeine Metabolism821
caffeine biosynthesis II (via paraxanthine)011
theobromine biosynthesis I09
caffeine biosynthesis I011
caffeine biosynthesis I012
caffeine biosynthesis II (via paraxanthine)012
caffeine degradation IV (bacteria, via demethylation and oxidation)016
caffeine degradation III (bacteria, via demethylation)521
Caffeine and theobromine metabolism011

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Guanine deaminaseHomo sapiens (human)Ki5.55001.88003.63405.5500AID502390
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
allantoin metabolic processGuanine deaminaseHomo sapiens (human)
nucleobase-containing compound metabolic processGuanine deaminaseHomo sapiens (human)
guanine catabolic processGuanine deaminaseHomo sapiens (human)
deoxyguanosine catabolic processGuanine deaminaseHomo sapiens (human)
nervous system developmentGuanine deaminaseHomo sapiens (human)
amide catabolic processGuanine deaminaseHomo sapiens (human)
GMP catabolic processGuanine deaminaseHomo sapiens (human)
dGMP catabolic processGuanine deaminaseHomo sapiens (human)
guanine metabolic processGuanine deaminaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
zinc ion bindingGuanine deaminaseHomo sapiens (human)
guanine deaminase activityGuanine deaminaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
cytosolGuanine deaminaseHomo sapiens (human)
cytosolGuanine deaminaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID394498Inhibition of Escherichia coli recombinant DNA gyrase-mediated supercoiling of relaxed pRSET A-DNA by agarose gel electrophoresis2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Discovery of novel DNA gyrase inhibitors by high-throughput virtual screening.
AID31881Binding affinity at Adenosine A1 receptor in rat brain cortical membrane using [3H]N6-R-phenylisopropyladenosine (R-PIA) as radioligand1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors.
AID502389Inhibition of GDA-mediated microtubule assembly2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Identification of small molecule compounds with higher binding affinity to guanine deaminase (cypin) than guanine.
AID502390Inhibition of GDA by colorimetric assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Identification of small molecule compounds with higher binding affinity to guanine deaminase (cypin) than guanine.
AID30807Binding affinity against Adenosine A2 receptor in rat striatal membranes using [3H]5'-(N-ethylcarboxamido)-adenosine (NECA) as the ligand1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.85)18.7374
1990's5 (19.23)18.2507
2000's4 (15.38)29.6817
2010's10 (38.46)24.3611
2020's6 (23.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.96 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index5.25 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]